Edwin Choy, MD, PhD

Panelists discuss how early recognition, accurate diagnosis through histopathology and molecular testing, and multidisciplinary collaboration are critical for optimizing treatment strategies in epithelioid sarcoma (ES), while future research into targeted therapies holds promise for improving outcomes, especially in advanced cases.

Panelists discuss how assessing disease progression, utilizing molecular testing (eg, INI1 loss), and considering prior treatment responses are crucial for selecting appropriate second-line therapies, with targeted therapies and immunotherapies offering promising options for managing advanced or metastatic epithelioid sarcoma (ES).

Panelists discuss how conventional chemotherapy remains a key frontline treatment for advanced or metastatic epithelioid sarcoma (ES), while emerging targeted therapies, guided by molecular profiling and biomarkers like INI1 loss, offer personalized treatment options for patients with specific molecular alterations.

Panelists discuss how a multimodal frontline treatment approach for epithelioid sarcoma (ES)—combining surgery, radiation, and systemic therapies—should be tailored to tumor resectability, disease stage, and patient-specific factors such as molecular characteristics and overall health.

Panelists discuss how neoadjuvant and adjuvant therapies, including chemotherapy and radiation, are used in localized epithelioid sarcoma (ES) to optimize surgical outcomes, reduce recurrence risk, and tailor treatment based on tumor characteristics and patient factors.

Panelists discuss how a real-world case of epithelioid sarcoma (ES) highlights the critical role of early recognition, comprehensive diagnostics including INI1 testing, and a multidisciplinary approach to personalize treatment based on disease extent, tumor location, and molecular features.

Panelists discuss how recognizing the diagnostic challenges of epithelioid sarcoma—including its histologic overlap with other conditions and the importance of INI1 loss as a key marker—can improve early detection and reduce misdiagnosis of this rare and aggressive tumor.

Panelists discuss how a comprehensive diagnostic approach—including advanced imaging, biopsy with immunohistochemistry for INI1 loss, and multidisciplinary evaluation—supports accurate diagnosis and staging of suspected epithelioid sarcoma while guiding personalized treatment planning.

Panelists discuss how recognizing the distinct histological patterns and the hallmark loss of INI1 expression in epithelioid sarcoma (ES) can enhance diagnostic precision, inform prognosis, and guide emerging targeted therapeutic strategies.

Panelists discuss how understanding the epidemiology, clinical presentation, and metastatic patterns of epithelioid sarcoma (ES) can support earlier recognition, accurate diagnosis, and more effective multidisciplinary management of this rare and aggressive soft tissue tumor.